Asian Pricing and Reimbursement

Ju Hyoung Lim, PhD

How to compete and succeed in a rapidly changing market

A land of pharma opportunity and financial challenges

Growing major trends are emerging across Asian healthcare markets. Rising incomes, increased government healthcare expenditure, higher life expectancies and a surge of chronic illnesses are boosting the demand for pharmaceutical products and services in the region. This sea of change is also being driven by multiple factors including government healthcare reforms, increasing Universal Health Coverage (UHC), the rise of private financing and heavy promotion of the generic market.

This offers a significant opportunity both for established pharmaceutical companies in the region who wish to continue to thrive and for those considering entering the Asian market. However, it also presents a unique set of regional challenges and commercial success will be dependent on understanding the complexities of the Asian pricing and reimbursement environment.

Opportunities within a changing Asian market

The Asian healthcare landscape is a dynamic one. The region consists of a wide diversity of healthcare markets in very different stages of development, particularly with regard to their healthcare infrastructure.

The healthcare environment within Asia is changing dramatically and spending in the region has shown an explosive rise in recent decades. Between 2009-2012 Asian markets showed the highest growth of per-capita healthcare spending in the world, at 38.8% of CAGR compared with the global average of 26.3%.1 The sharp increase of healthcare spending in this region can be explained by several factors, including growing economies, expansion of the middle class, the rise of chronic illness and increased life expectancy.

To meet this rapid growth, Asian healthcare systems will need to expand and adapt. As more countries implement healthcare reforms, leading to greater patient population coverage, countries across Asia will need to address pricing and reimbursement challenges to meet healthcare demands.

Deallus Asian Pricing & Reimbursement Whitepaper
DOWNLOAD WHITE PAPER

About the author

Ju Hyoung Lim, PhD

Ju has played a pivotal role within Deallus to expand our presence in Asian markets, driving business growth throughout Singapore, Japan, and China. Ju works closely with clients in order to manage and support both regional and global projects. He has extensive experience in competitive intelligence, portfolio planning, indication scoping, forecasting, product planning, and workshop design.

More about Ju

You may also be interested in…

  • Leading in a Crisis: Driving Value for Your Customers, Your Organization, and Yourself

Episode 2: Leading in a crisis

Join Peter Hempshall, Deallus CEO, and Rita Numerof, President of Numerof & Associates for Episode 2 of their discussion series - Leading in a crisis. This episode will explore topics around how leaders can manage effectively during a crisis and continue to deliver value for their customers, their organizations, and for themselves. Any business leader eager to explore tactics, best practices, and learning experiences gained from leading in times of uncertainty will find value in this episode.

Remdesivir’s journey and its impact on share price

The COVID-19 pandemic will shape several future market trends within the pharmaceutical industry. In terms of emerging macro trends, one notable impact of COVID-19 has been on the stock market within the healthcare sector, historically considered a safe haven for investors during financial crises. Our infographic plots significant events in Remdesivir’s recent history to contextualize this dramatic story and the seemingly disproportionate impact one product’s journey appeared to have on the overall company stock price.

OnDemand Webinar – Navigating Market Disruption after COVID-19

Peter Hempshall, Deallus CEO, and Rita Numerof, President & Co-Founder of Numerof & Associates, have joined forces to generate thought-provoking discussions on ‘Navigating Market Disruption After Covid-19’. This OnDemand webinar discusses how the pandemic has accelerated market shifts already in play, disrupting current business models, and dramatically altering how pharma business will be done in the future.

Deallus Virtual Workshop on Competitive Insight at EyeforPharma 2020

What is a ‘competitive insight’? How do you make it actionable? These were the two key questions we focused on at EyeForPharma. Competitive Insights are the secret sauce that generate Competitive Advantage from Strategic Intelligence and point to opportunities of impact where it matters most. We offered participants a compressed but unique hands-on experience of generating competitive insights and focused on understanding how to make them truly actionable.